StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) KPIs and segments

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)

Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –

KPIs & segments

Operating metrics and segments that drive Lakefront Biotherapeutics's business

Lakefront Biotherapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Research and Development Segment(€M)
83527911812234.1
Fee for services segment(€M)
10.110.28.837.905.43
North America(€M)
79611882.1
United States(€M)
47279411782.188.617.1
Europe(€M)
5.6141.016245.040.922.4
Asia Pacific(€M)
0.360.110.010.04
Research and Development Segment(€M)
407-19.7-73.61.14-82.0
Fee for services segment(€M)
1.131.750.09-1.79-2.69

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2021-03-25.

See a number that looks wrong?